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Abstract
Background: Inhaled corticosteroids (ICS) are a cornerstone of asthma treatment. 
However, their efficacy is characterized by wide variability in individual responses.
Objective: We investigated the association between genetic variants and risk of exac-
erbations in adults with asthma and how this association is affected by ICS treatment.
Methods: We investigated the pharmacogenetic effect of 10 single nucleotide poly-
morphisms (SNPs) selected from the literature, including SNPs previously associated 
with response to ICS (assessed by change in lung function or exacerbations) and novel 
asthma risk alleles involved in inflammatory pathways, within all adults with asthma 
from the Dutch population– based Rotterdam study with replication in the American 
GERA cohort. The interaction effects of the SNPs with ICS on the incidence of asthma 
exacerbations were assessed using hurdle models adjusting for age, sex, BMI, smoking 
and treatment step according to the GINA guidelines. Haplotype analyses were also 
conducted for the SNPs located on the same chromosome.
Results: rs242941 (CRHR1) homozygotes for the minor allele (A) showed a significant, 
replicated increased risk for frequent exacerbations (RR = 6.11, P < 0.005). In contrast, 
rs1134481 T allele within TBXT (chromosome 6, member of a family associated with 
embryonic lung development) showed better response with ICS. rs37973 G allele 
(GLCCI1) showed a significantly poorer response on ICS within the discovery cohort, 
which was also significant but in the opposite direction in the replication cohort.
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1  |  INTRODUC TION
Asthma is a chronic heterogeneous airway disease, presenting 
worldwide in different clinical phenotypes and molecular endo-
types, affecting up to 300 million people.1- 3 Asthma's hallmark 
features are airway hyper- responsiveness and reversible airway 
obstruction. Inflammation not only occurs mainly in the bronchi 
and conducting trachea, but may also spread up to the alveoli with 
more severe symptoms. The underlying pathology is not yet fully 
understood. It is believed that immune- mediated inflammatory 
processes have a significant role in asthma, especially T helper 2 
(Th2) cells and type 2 innate lymphoid cells (ILC2), which mediate 
inflammation and induce eosinophilia through interleukin media-
tors.4 NF- Kb (k is actually greek kappa) is also regarded to be an 
important pathway of inflammation in asthma, and its upregula-
tion was found to be of special importance in severe uncontrolled 
asthma.5
Asthma is increasingly recognized as a disease with a major 
genetic component, as heritability is estimated to be 35%- 70%.6,7 
According to the GWAS catalog, 646 single nucleotide polymor-
phisms (SNPs) have been associated with asthma, including variants 
associated with different phenotypes of the disease (eg childhood- 
onset asthma, severe asthma).8,9 Shrine et al.10 pinpointed genetic 
loci associated with severe asthma phenotypes, confirming the 
earlier findings suggesting genetic factors to be involved in disease 
severity.11,12 Moreover, environmental factors may also influence 
the risk of asthma onset and severity, possibly through epigenetic 
mechanisms.13,14
The current asthma guidelines recommend inhaled corticoste-
roids (ICS) as first- line therapy for persistent asthma, with intensi-
fication based on the patient's response.15 Corticosteroids exert a 
range of anti- inflammatory effects including by decreasing the ex-
pression of pro- inflammatory genes, as well as upregulation of anti- 
inflammatory genes. Corticosteroids bind to specific glucocorticoid 
receptors affecting the expression and transcription of a multitude 
of genes involved in the inflammatory process. Most importantly, 
ICS anti- inflammatory effects reduce the risk of asthma exacerba-
tions, considered one of the most important components in estab-
lishing disease control in patients with asthma.16- 18 ICS may also 
potentiate beta2- adrenergic agonists.
19
However, individual response to ICS is widely recognized to 
be highly variable20,21 and up to 10% of patients require a maxi-
mal dose of ICS.22 Furthermore, a significant proportion of adults 
with asthma have exacerbations despite adequate treatment with 
ICS.21 This variability may be the result of several factors. Besides 
adherence and inhaler technique, the mechanism of inflammation 
underlying the asthma phenotype is important. No standardized 
clinical test or biomarker exists to predict ICS response. Previous 
attempts to identify predictors included the age of asthma onset, 
sex and the fraction of exhaled nitric oxide (FeNO). Additionally, 
short- term response, defined as six weeks of ICS treatment, and 
history of exacerbations were also identified as predictors for dis-
ease control by ICS, as assessed by reduced risk of further exacer-
bations in the long term.23- 25
Identification of individuals with asthma with poor response to 
ICS therapy may be useful, as these individuals may benefit from 
earlier interventions with other therapies. This variability of re-
sponse to ICS treatment in patients with asthma may not only be 
due to different mechanisms and types of airway inflammation, 
but may also partly be attributed to pharmacogenetics.26 Several 
genome- wide and candidate gene studies have been conducted 
to evaluate the effects of genetic variants on ICS response.27- 32 
McGeachie et al. previously combined two genetic variants in a 
test to predict ICS response.33 However, genetic variants are not 
yet used in clinical practice to predict ICS response, as most dis-
covered loci had a relatively small effect on the drug response, 
leading to limited potential clinical utility even in the largest 
GWAS conducted to date.33- 35 Furthermore, few studies have in-
vestigated the genetic association with ICS effects on exacerba-
tions in adults with asthma, despite evidence of variability for this 
important age group as well.21- 37
Several interesting SNPs may potentially affect patients’ re-
sponse to ICS. For example, two variants (rs28364072 and 
rs7216389) were previously associated with increased exacerba-
tions risk in children treated with ICS30- 38 and five variants were 
previously associated with ICS response based on changes in lung 
function (FEV1).29- 40 In addition, three novel SNPs associated with 
asthma41 could affect treatment response through their effects on 
the expression of three genes affecting important inflammatory 
pathways: rs17637472, a strong cis- eQTL for G Protein Subunit 
Gamma Transducin 2 (GNGT2); rs7705042 located within an intron 
of Nedd4 Family- Interacting Protein 1 (NDFIP1); and rs167769, an 
intron variant of STAT6 gene.41
The main objective of this study was to investigate whether the 
ten above- described genetic polymorphisms (Table 1) modulate the 
treatment response to ICS in adult patients with asthma.
Conclusion: rs242941 in CRHR1 was associated with poor ICS response. Conversely, 
TBXT variants were associated with improved ICS response. These associations may 
reveal specific endotypes, potentially allowing prediction of exacerbation risk and ICS 
response.
K E Y W O R D S
asthma exacerbations, inhaled corticosteroids, personalized medicine, pharmacogenetics
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2  |  METHODS
2.1  |  Setting and study population
2.1.1  |  Discovery cohort
We investigated all patients with asthma (n = 775) within the Rotterdam 
study, an ongoing prospective population- based cohort study involving 
inhabitants of the Ommoord district of Rotterdam, the Netherlands.42 
The rationale and design of the Rotterdam study have been described 
elsewhere.43 In short, the Rotterdam study includes three subcohorts 
RS I, RS II and RS III. Baseline data were collected from 1989 to 1992 in 
RS I (n = 7983), from 2000 to 2003 in RS II (n = 3011) and from 2006 to 
2009 in RS III (n = 3932). Follow- up examinations were conducted peri-
odically based on a home interview and an extensive set of tests at the 
research facility. In addition, data from the medical records of the gen-
eral practitioners (GPs), nursing homes and hospitals were collected. 
The Rotterdam study is approved by the Medical Ethics Committee 
of the Erasmus Medical Center, Rotterdam (registration number MEC 
02.1015), and the review board of the Netherlands Ministry of Health, 
Welfare and Sports (Population Screening Act WBO, license number 
1071272- 159521- PG). The Rotterdam Study Personal Registration 
Data collection is filed with the Erasmus MC Data Protection Officer 
under registration number EMC1712001. Written informed consent 
was obtained from all participants.
2.2  |  Replication cohort
Replication was based on data from the Kaiser Permanente Northern 
California (KPNC) multi- ethnic Genetic Epidemiology Research on 
Adult Health and Aging (GERA) cohort, which comprises longitudi-
nal electronic health record data on over 100 000 people.44 Data 
included longitudinal asthma- related events, such as ambulatory 
office visits, hospitalizations, emergency department (ED) visits, 
and fills of ICS and ICS- LABA combination. Follow- up started from 
the start of their first ICS prescription. The institutional review 
boards for human subject research of both KPNC and University of 
California, San Francisco (UCSF), approved the project (AG036607; 
Schaefer/Risch, PIs). Patients from non- European ancestries were 
excluded from the analysis, as the Rotterdam cohorts consist mainly 
of subjects with European Ancestry.
2.3  |  Definition of cases and controls
Participants in the Rotterdam study were considered to have asthma 
if diagnosed by a physician and reported in their medical file.42 The 
start date of follow- up was defined as the diagnosis date for incident 
cases or the date of study enrolment for prevalent asthma subjects. 
Subjects were followed until death, loss to follow- up or the end of the 
study period (1 January 2016), whichever came first. In the GERA co-
hort, subjects were considered to have asthma based on their elec-
tronic health records and follow- up started from the start of their first 
ICS prescription and included up to 15 years of follow- up. Asthmatic 
subjects experiencing one or more asthma exacerbations during the 
follow- up period were compared with asthma subjects without an ex-
acerbation during the follow- up period.
2.4  |  Asthma exacerbations
In the Rotterdam study, asthma exacerbations were defined as the 
worsening of asthma requiring the use of short- term systemic corti-
costeroids for at least three days, according to the American Thoracic 
Society (ATS)/European Respiratory Society (ERS) statement.18 
TA B L E  1  SNPs selected to test for their effects on asthma exacerbations in adults treated with ICS
Gene Location on chromosome Variant
Minor 
allele
Minor allele frequency 
(European) (%)
Novel variants being investigated
GNGT241 17q21.33 rs17637472 A 39
NDFIP141 5q31.3 rs7705042 C 36
STAT641 12q13.3 rs167769 T 33
Variants with documented effects on exacerbations (in children)
FCER238 19p13 rs28364072 G 28
GSDMB30 17q12- 21 rs7216389 T 13
Variants with documented effects on lung function measured by ∆FEV1
GLCCI129- 34 7p21.3 rs37973 G 44
CRHR134- 40 17q21.31 rs242941 A 28
TBXT (T- box transcription factor) gene 
locus39,40
6q27 rs1134481 T 40
rs2305089 C 50
rs3099266 T 42
Abbreviation: FEV1, forced expiratory volume.
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Exposure to systemic corticosteroids was assessed using medication 
dispensing data (ATC codes: H02). Prescriptions with less than 7 days 
of difference between end date of the previous prescription and start 
date of the subsequent one were considered to indicate the same 
episode. Asthma exacerbations in the GERA replication cohort were 
defined as an asthma- related ED visit, hospitalization or oral corticos-
teroid (OCS) burst. OCS bursts were defined as single OCS prescrip-
tions, excluding long- term OCS use as a controller medication.
2.5  |  Drug exposure
Medication dispensing data were obtained from all seven fully com-
puterized pharmacies in the study district in the Rotterdam study, and 
medication filling data were obtained from the electronic records in 
the GERA cohort. Within the Rotterdam study, records of all filled 
prescriptions from 1 January 1991 onwards were available and in-
cluded information on the product name, the ATC codes, the dispens-
ing date, the prescribed dosing regimen and the amount dispensed. 
The prescribed daily dose of each ICS was expressed in standardized 
defined daily doses according to the ATC/DDD system of the World 
Health Organization (Anatomical Therapeutic Chemical Classification 
System/ defined daily doses).45 The studied inhaled corticosteroids 
included ICS monotherapy (ATC codes: R03BA01- 9) and ICS combi-
nation therapy (ATC codes: R03AK06- 13). ICS exposure was assessed 
based on pharmacy dispensing data on start of and during the follow-
 up period. Subjects were considered ICS users if their prescribed ICS 
covered 80% or more of their total follow- up time.
2.6  |  Genetic variants
We extracted the dosage of 10 SNPs in the Rotterdam study with 
minor allele frequency ≥5% (Table 1). The SNPs were selected based 
on a systematic review of the available literature on SNPs associ-
ated with asthma. The search strategy is described in the File S1. 
Genotyping was performed using Illumina 500 (+duo) and Illumina 
Human 610- Quad BeadChips. Imputation quality for the inves-
tigated SNPs was high (at least ≥0.85). For the functional annota-
tion of the variants, we checked their predicted functions, including 
effects on gene regulation, protein structure and splicing by using 
the HaploRegv4.1 (http://www.broad insti tute.org/mamma ls/haplo 
reg/haplo reg.php). Haploview 4.2 and LDLINK were both used to 
estimate haplotype population frequency and linkage disequilibrium 
between SNPs.46 DNA extraction, genotyping, array design and 
population structure analyses for the GERA cohort have been previ-
ously described.44- 49
2.7  |  Statistical analysis
Descriptive statistics were calculated using means and standard 
deviations for continuous variables and using percentages for 
categorical variables. Given the primary outcome zero- inflated 
distribution in the discovery cohort, hurdle regression models 
were used to calculate the odds ratios for the first exacerbation 
and rate ratios for further exacerbations during the follow- up 
period. Interaction terms were used to check whether genetic 
variants modify the ICS treatment response on exacerbation risk. 
The hurdle model consists of two stages, the first step models 
the risk of having an exacerbation count above zero, and the sec-
ond step models the risk of having more frequent exacerbations 
(ie risk of additional exacerbations for subjects with at least one 
exacerbation).50 As follow- up periods varied between subjects, 
logarithm of the follow- up times was used as an offset variable 
in the model. The study design and follow- up of both discovery 
and replication cohorts have been illustrated in Figure S1. Full 
models were adjusted for covariates that were significantly (or 
clinically) related to the exposure and changed the point estimate. 
Significant difference was calculated using the t test for continu-
ous variables (age, BMI, pack- years of cigarette smoking) and the 
chi- square test for categorical variables (sex, medication use and 
smoking status). To account for potential confounding by disease 
severity, treatment steps— according to GINA guidelines— were 
categorized using level of ICS use and other asthma comedica-
tions.51 The final models were therefore adjusted for BMI, sex, 
age at baseline, smoking and the highest GINA treatment step. 
Finally, interaction terms were included in the full model, to in-
vestigate the effects of genotype on drug response according to 
the following formula:
All statistical analyses were performed using SPSS version 25 
(SPSS Inc., Chicago, IL) and R Statistical Software version 1.1.463 
(R Foundation for Statistical Computing, Vienna, Austria).52 The 
package pscl was used to fit the hurdle models.53 Haplo.stats, an 
R package, was used for haplotype analysis.54 Because we tested 
10 SNPs, a Bonferroni- corrected P value below 0.005 (0.05/10) was 
considered statistically significant. Subjects with missing genotype 
or covariable data were excluded.
3  |  RESULTS
Within the Rotterdam study population, 12,453 subjects were geno-
typed, 11,496 of them passed the quality control, and 11,385 par-
ticipants gave informed consent for retrieving follow- up data. There 
were 325 asthmatic cases with at least one exacerbation during 
follow- up and 272 adults with asthma without an exacerbation dur-
ing follow- up with available genotype and covariable data (Figure 1). 
From the 13761 asthmatic subjects within the GERA replication co-
hort, 2787 were excluded due to their different ancestries, 775 were 
excluded for being followed for less than a year, and 357 were not in-
cluded in the analysis due to missing data. From the remaining, 7978 
E[
Total number of exacerbations
Years of follow up as offset term
]=0+1SNP× ICSuse+2SNP+3ICSuse
+4Age+5Sex+6BMI+7Smoking+8GINA Treatment step
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adults with asthma had exacerbations and 1864 adults with asthma 
had no exacerbations during the follow- up starting from their first 
ICS prescription. Adults with asthma with exacerbations were older, 
used more (frequently) ICS and were therefore more likely to be in 
higher GINA treatment steps in both the discovery and replication 
cohorts (Table 2).
3.1  |  Pharmacogenetic effects on exacerbation risk 
(zero model)
Only rs17637472 heterozygotes showed a nominally signifi-
cantly improved response with ICS in both crude and full models 
(Table 3, Table S1) compared with wild- type individuals (OR: 0.24, 
P = 0.012).(Table 3) Despite a similar direction of effect for this 
SNP in the zero model of the replication (Table 4), no SNPs were 
significantly associated with ICS response to prevent the first ex-
acerbation, adjusted for age, sex, smoking, BMI and GINA treat-
ment step (Tables 3 and 4).
3.2  |  Pharmacogenetic effects on recurrent 
exacerbation risk (positive count model)
Three variant alleles were associated with an increased risk of 
recurrent exacerbations by ICS use in the positive count model 
(Table 3). rs242941 homozygotes for the minor allele (A) of CRHR1 
were at more than sixfold increased risk for exacerbations when 
using ICS (RR:6.11; P < 0.005; Figure 2), and rs7705042 homozy-
gotes for the minor allele (C) had an incidence rate ratio of 2.44 
(P < 0.005) when using ICS. The minor allele (G) of rs37973 showed 
increased risk by ICS use for both homozygotes and heterozygotes 
carriers, but only heterozygotes passed the Bonferroni threshold. 
Three SNPs (rs1134481, rs2305089 and rs3099266)— associated 
with TBXT gene— showed better response with ICS within the 
population- based Rotterdam study. A significantly decreased risk 
of subsequent exacerbations was also observed for heterozygous 
rs167769 ICS users, but this effect was not significantly extended 
to the homozygous variant carriers, nor was it replicated (Tables 3 
and 4, Table S2).
F I G U R E  1  Study flow, including 
both the discovery and the replication 
phases
Asthma subjects in the Roerdam 
Study (n=775)
Adults with asthma with at least one 
exacerbaon (n=325)
Adults with asthma without
exacerbaons (n=272)
Asthma subjects included in our 
analysis (n=597)
Subjects with missing 
genotype informaon 
(n=165)
Subjects followed for less 
than 1 year (n=3)
Subjects with missing 
covariable data (n=10)
Asthma subjects in the GERA Cohort 
(n=13761)
Adults with asthma with at least one 
exacerbaon (n=7978)
Asthma subjects included in our 
analysis (n=9842)






Subjects followed for less than 
1 year (n= 775)
Subjects with missing 
covariable informaon (n= 357)
Adults with asthma without
exacerbaons (n=1864)
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Results for the replication analysis for the 8 SNPs with significant 
associations in the discovery cohort are outlined in Table 4. Effects of 
SNPs rs242941 and rs1134481 by ICS use showed the same direction 
of association as the discovery cohort in their count model and passed 
the Bonferroni threshold. rs37973 showed a very significant associa-
tion but in the opposite direction compared with the discovery cohort.
Three of our selected SNPs were located on the same chromo-
some (chromosome 6) in the T- box transcription factor (TBXT) gene 
locus (Figure S2). The three SNPs were in high linkage disequilib-
rium (LD) (R2>0.67, D’> 0.96). Haplotype frequencies for a European 
population were estimated as follows: GTC: 49.4%; TCT: 39.0%; 




SNP by ICS 
interaction effect 
on exacerbation risk 
(Zero part of the 
hurdle model)












47.7 0.24 0.011 0.96 0.635
GAAA 17.4 0.71 0.666 1.09 0.777
rs7705042 NDFIP1
AC 45.0 1.09 0.864 0.93 0.609
CC 13.4 1.49 0.687 2.44 <0.005
rs167769 STAT6
CT 47.6 0.65 0.413 0.52 <0.005
TT 13.2 2.03 0.462 0.86 0.498
rs28364072 FCER2
43.0 1.09 0.868 0.84 0.188
CG AG 7.7 1.27 0.787 1.12 0.744
rs7216389 17q21
CT 52.8 1.13 0.836 1.36 0.069
TT 21.1 1.17 0.829 1.19 0.374
rs37973 GLCCI1
GA 52.2 1.86 0.277 1.88 <0.005
GG 15.6 0.64 0.532 1.54 0.043
rs242941 CRHR1
CA 51.2 0.59 0.330 1.27 0.079
AA 5.5 0.46 0.506 6.11 <0.005
rs1134481 TBXT
GT 44.2 1.17 0.768 0.68 0.006
TT 17.9 3.87 0.135 0.36 <0.005
rs2305089 TBXT
TC 47.7 1.00 0.993 0.42 <0.005
CC 25.9 3.25 0.149 0.37 <0.005
rs3099266 TBXT
GT 47.9 1.20 0.732 0.58 <0.005
TT 19.1 4.40 0.103 0.29 <0.005
Odds ratios, rate ratios and their corresponding P values of the association between the SNPs and 
increased or decreased risks in both zero and count models, adjusted for age, sex, smoking, BMI 
and GINA treatment step. Underlined associations are nominally significant, bolded associations 
have passed the Bonferroni threshold.
Abbreviations: ICS, inhaled corticosteroid; OR, odds ratio; RR, rate ratio; SNP, single nucleotide 
polymorphism.
TA B L E  3  Results of the adjusted hurdle 
models for the 10 selected SNPs in the 
discovery cohort (n = 597)
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had the TCT haplotype. Subjects homozygous for the haplotype 
(TCT) using ICS were at a decreased risk of recurrent exacerbations 
compared with the wild haplotype (RR: 0.41; P < 0.005) (Table S3). 
However, this association was not replicated in the replication co-
hort. To better reflect the same exacerbation definition in the rep-
lication as the discovery cohort, we have performed a sensitivity 
analysis excluding exacerbators based on ED visits and hospitaliza-
tion only (n = 1600) and observed similar effect estimates for the 
three replicated results.
Regarding the SNP main effects (Tables S4 and S5), homozy-
gotes of the minor allele of rs7216389 and rs37973 had a signifi-
cantly increased frequent exacerbation risk in both discovery and 
replication cohort. rs242941 heterozygotes had a significantly 
decreased risk of frequent exacerbations in the discovery cohort 
(Table S4), yet a significantly increased risk in the replication co-
hort (Table S5). Homozygotes of the minor allele of rs1134481, 
rs2305089 and rs3099266 within the TBXT gene demonstrated a 
significantly increased frequent exacerbation risk in the discovery 
cohort (Table S4).
4  |  DISCUSSION
In this largest pharmacogenetic candidate gene study on exacerba-
tions in adults with asthma to date, eight of 10 investigated polymor-




SNP by ICS 
interaction effect 
on exacerbation risk 
(Zero part of the 
hurdle model)












GA 47.6 0.68 0.163 1.04 0.174
AA 16.1 0.74 0.415 1.03 0.428
rs7705042 NDFIP1
AC 46.1 1.18 0.508 0.98 0.628
CC 13.2 1.43 0.354 0.96 0.429
rs167769 STAT6
CT 47.6 1.25 0.396 1.05 0.071
TT 15.1 1.06 0.851 1.10 0.023
rs37973 GLCCI1
GA 49.2 1.44 0.176 0.92 <0.005
GG 18.9 1.25 0.528 0.82 <0.005
rs242941 CRHR1
CA 42.6 1.27 0.327 0.99 0.924
AA 9.9 3.07 0.074 1.16 0.004
rs1134481 TBXT
GT 48.3 0.81 0.416 0.92 <0.005
TT 14.3 1.13 0.764 1.02 0.563
rs2305089 TBXT
TC 50.8 0.71 0.241 1.01 0.782
CC 26.3 0.80 0.533 0.95 0.171
rs3099266 TBXT
GT 48.8 0.92 0.764 0.97 0.383
TT 16.0 0.95 0.899 0.99 0.975
Legend: Odds ratios, rate ratios and their corresponding P values of the association between 
the SNPs and increased or decreased risks in both zero and count models, adjusted for age, sex, 
smoking, BMI and GINA treatment step in the replication cohort. Underlined associations are 
nominally significant, bolded associations have passed the Bonferroni threshold.
Abbreviations: RR, rate ratio, OR, odds ratio ICS, inhaled corticosteroid, SNP, single nucleotide 
polymorphism.
TA B L E  4  Results of the adjusted hurdle 
models for 8 SNPs in the replication 
cohort (n = 9842)
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in adults with asthma. In an independent replication cohort, three of 
these eight SNP by ICS interactions passed the Bonferroni threshold 
with the same direction of effect for two polymorphisms: rs242941 
(CRHR1) homozygotes for the minor allele were at increased risk for 
frequent exacerbations upon ICS treatment, while rs1134481 (TBXT 
gene) minor allele carriers showed better response with ICS in both 
discovery and replication cohort. Interestingly, rs37973 (GLCCI1) sig-
nificantly increased exacerbation risk by ICS use in the Dutch discov-
ery cohort, but had an opposite direction of effect in the American 
replication cohort.
Homozygotes of the rs1134481— located within the T- box tran-
scription factor T (TBXT) gene— minor allele showed better response 
with ICS in both cohorts. rs1134481 homozygous mutants have 
previously been shown to have a favourable response to ICS.39 The 
T gene (also called T Brachyury) belongs to a family of genes called 
the T- box family, a highly conserved family of transcription factors 
with widespread roles in embryonic and stem cell development.55 
Mutations may result in developmental syndromes in humans and in 
other vertebrates, such as mice.56 T Brachyury encodes for a protein 
that binds to a palindromic site (called T- site), upregulating genes re-
quired for mesoderm formation and differentiation.55- 57 T Brachyury 
is expressed in lung tissue58 as well as other members of the T- box 
family, including TBX4, TBX5 and TBX21, a family member linked to 
childhood asthma,59 aspirin- induced asthma 60 and improvement 
in FEV1 during an asthma exacerbation in children receiving high- 
dose ICS.40 The effects of this gene on exacerbation risk in adult 
ICS users may represent a highly corticosteroid responsive asthma 
phenotype, as its SNPs’ main effects showed increased frequent ex-
acerbation risk, which seems to be effectively reduced with ICS use. 
This phenotype might already benefit from interactions with endog-
enous glucocorticoids during fetal and neonatal lung development. 
Endogenous glucocorticoids were found to be crucial to early lung 
development through their effects on lung cell maturation, differ-
entiation and the production of surfactant- related proteins.61 It has 
also been suggested that decreased T gene expression may inhibit 
chondrogenesis, through mediator proteins involved in corticoste-
roid resistance.31- 63 In the Dutch population, ICS was more effective 
in the count model for minor allele homozygotes of the haplotype 
consisting of rs1134481, rs2305089 and rs3099266, further impli-
cating a potential role for this genetic locus in ICS response on exac-
erbations in adults with asthma.
Corticotrophin- releasing hormone receptor 1 (CRHR1) rs242941 
mutant carriers demonstrated the strongest association with a more 
than sixfold increased exacerbation risk upon ICS use (RR: 6.11). 
Although the effect was less pronounced but still Bonferroni signif-
icant in the replication analysis, it is important to note that its effect 
was already threefold increased in the replication zero model (OR: 
3.07). Therefore, though the portions of the model may be different, 
the risk allele may be globally associated with a substantial increase in 
exacerbation risk while on ICS. rs242941 is an intronic variant previ-
ously linked to improved lung function response to ICS over 8 weeks 
in asthma,64 although it was not statistically significant in a large 
GWAS studying ICS response in patients with asthma.35 Moreover, 
rs242941 was also associated with good initial (sustained for 60 min-
utes) response to inhaled corticosteroids in asthmatic Indian children 
experiencing an acute exacerbation.65 Independent of treatment, 
rs242941 heterozygotes demonstrated a significantly decreased 
risk of frequent exacerbations in the Dutch discovery cohort but a 
significantly increased risk in the American replication cohort. Since 
the SNP is linked to corticotrophin- releasing hormone, the long- term 
effects by interfering these inflammatory pathways within asthma's 
pathophysiology by anti- inflammatory treatment warrant further 
investigation.66 CRHR1 is highly expressed in brain tissues (hippo-
campus, cortex and cerebellum).67,68 It encodes a G protein– coupled 
receptor, essential for activating signal transduction pathways af-
fecting the hypothalamic- pituitary- adrenal pathway and the normal 
hormonal responses to stress and anxiogenic stimuli.69 Besides reg-
ulation of stress and immune responses, involvement into obesity 
and cAMP- dependent protein kinase and glucocorticoid pathways 
has also been described.70- 72 Interestingly, variation in CRHR1 has 
also been linked to the incidence of depression,68- 74 an important 
asthma comorbidity 75 associated with increased risk of hospital-
ization in patients with asthma.76 Additionally, CRHR1 variants have 
been associated with variability in antidepressant response.77,78
Though the direction of our long- term effects for this SNP in adults 
and elderly with asthma differs from previously published studies 
F I G U R E  2  Exacerbation rate per 
rs242941 genotype (Discovery cohort). 
Legend: Boxplot illustrating exacerbation 
rates per rs242941 genotype (CC: 
135 patients, CA: 177 patients, AA:17 
patients) in subjects with at least one 
exacerbation, stratified by ICS use. The 
boxplots width represents the proportion 
of the genotype among the subjects in 
their respective strata. The minor allele 
(A) homozygotes (17 patients, 2 ICS 
users) show a significantly increased 
exacerbation rate, despite their small 
proportion
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on acute effects in mainly asthmatic children,64,65 it is worth noting 
that our results are in line with effects observed in COPD patients.79 
Therefore, this contrast may be either due to difference in outcome 
defined as long- term recurrent exacerbations versus short- term lung 
function response or due to different age groups. It may be suggested 
that subjects carrying the variant show a good initial pulmonary re-
sponse to ICS, but fail to improve in long- term outcomes. It may also 
be suggested that the subset of frequent exacerbators carrying these 
genotypes represent a subgroup of patients with severe irresponsive 
asthma, who may benefit from early treatment with additional agents 
or only respond to higher corticosteroid doses. Alternatively, since the 
previous studies were mainly conducted on children cohorts, environ-
mental exposures resulting in severe asthma and frequent exacerba-
tions may be affecting the genotype- phenotype associations over the 
course of life.80 Finally, the number of patients with minor allele homo-
zygotes (AA) who were classified as ICS users in the discovery cohort 
was small. Nevertheless, the variant may still be relevant for 5%- 10% of 
patients with asthma, or for populations with an even higher frequency 
of the risk allele. Interestingly, the A allele has an even higher frequency 
in African- ancestry populations (64%),81 and further studies may shed 
light on the variant role in African- ancestry patients with asthma.
Some associations initially detected in the Dutch cohort were 
not replicated in the independent American cohort. rs37973 within 
the Glucocorticoid- Induced Transcript 1 (GLCCI1) showed a signifi-
cantly poor ICS response in line with previous observations of de-
creased response to ICS in GLCCI1 polymorphic asthmatic patients 
in the Dutch cohort, but had a significantly yet opposite direction of 
effect in the American cohort.29 Interestingly, the SNP main effect 
showed a significantly increased frequent exacerbation risk in both 
the discovery and replication cohort. The gene expression of GLCC1 
is known to be induced by glucocorticoids, and it has been described 
to be an essential mediator of glucocorticoid- induced T- cell apopto-
sis.82 Non- replicated results could still be in part due to different pa-
tient recruitment and follow- up strategies. Since the follow- up in the 
replication cohort started from their first registered ICS prescription 
(instead of study start or asthma incident date in the discovery co-
hort), it is likely that for some, the zero model already describes the 
SNP by adherent ICS effect on subsequent exacerbations if an ex-
acerbation already occurred before the first registered ICS prescrip-
tion. Moreover, exacerbations in the GERA cohort included both 
hospitalizations and moderate- to- severe exacerbations, while ex-
acerbations in the Dutch cohort only included moderate- to- severe 
(OCS bursts) exacerbations. In addition, our analysis only included 
patients of non- Hispanic European White ancestry, and therefore, 
the results may differ among other ethnicities.83- 85 Moreover, our 
models did not include other potential factors that could have af-
fected response to inhaled corticosteroids, including atopy status 
and environmental effects, and adding these could have increased 
our explained proportion of the variance in treatment response fur-
ther, although differences in environment during the study period 
are minimized in our discovery cohort since all participants were re-
cruited from the same district in the city of Rotterdam. Additionally, 
while our calculations assumed an additive model, it is possible that 
some of our loci follow different models (eg recessive or dominant).86 
Finally, it should be noted that while the use of pharmacy prescrip-
tion records provides accurate information on the drugs prescribed 
by physicians and dispensed by pharmacies, this may not fully reflect 
patients’ adherence to their therapeutic regimen.
Our study uniquely focuses on the long- term risk of exacerba-
tions in real- life adults and elderly with asthma, and takes for the 
first time the important impact of ICS adherence into account when 
investigating the attributable role of pharmacogenetics into variable 
treatment response.87 Although this reduced number of true ICS 
users may have limited our power to detect or replicate some inter-
action effects, we are convinced that the gained exposure specificity 
is a strength and important in estimating true effect sizes of vari-
ants directly affecting medication response. We used special types 
of count models— hurdle models— to be able to assess the real- life 
variability in asthma severity over a longer time period, adding to 
potential clinical implications, as patients who experience one exac-
erbation are at a high risk of a second exacerbation.88 Our analysis 
divides risk into two different questions: first, factors affecting ini-
tial risk of having an exacerbation (primary prevention in the general 
population); and second, factors affecting subsequent exacerbation 
risk, meaning how often will a participant have exacerbations once 
they already have had one (secondary prevention in a clinical asthma 
population). We believe this to be an important strength of our study, 
as exacerbations are a major burden for patients and health systems, 
but their primary prevention may differ from secondary preven-
tion.89 Previous studies have investigated the associations between 
rs37973, rs242941 or TBXT gene locus variants and ICS response 
using FEV1 as marker of short- term response to therapy.90 However, 
a large GWAS could not confirm any of the previously reported asso-
ciations.35 Although long- term outcomes may be modelled through 
lung function response as well,91 establishment of genetic predic-
tors for exacerbations, an important long- term clinical outcome of 
asthma, has a significant potential for classification and prediction 
of asthmatic response to maintenance therapy. Medication effects 
have also been shown to vary between long- and short- term out-
comes. For example, long- acting beta- agonists improve lung func-
tion, but their single use leads to increased risk of exacerbations and 
mortality.92,93 It may also be suggested that the SNPs previously 
associated with asthma exacerbations in children (rs7216389 and 
rs28364072) were differently associated with the outcome in our 
study due to age differences, highlighting the heterogeneity in the 
disease mechanism between adult and childhood asthma, possible 
gene- environment interactions and therefore the limitations of ex-
trapolating genetic results between children and adults in asthma.
5  |  CONCLUSION
Genetic variants may affect the efficacy of ICS in reducing the risk 
of exacerbations in adult asthma. rs242941 (a CRHR1 variant) was 
associated with reduced ICS effects on exacerbations, while vari-
ants in TBXT were associated with increased response. GLCCI1 minor 
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allele, previously linked to FEV1 change in adults with asthma using 
ICS, leads to an increased risk of recurrent exacerbations only in the 
discovery cohort. Further research on these genetic loci, and their 
potential effects in adults with asthma, may help clarify their pre-
dictive role in ICS response and the development of asthma pheno-
types and endotypes.
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